<DOC>
	<DOCNO>NCT00963755</DOCNO>
	<brief_summary>The purpose study demonstrate realization guide biopsy multimodal image 18F-fluorocholine PET / CT MR Imaging/spectroscopy would allow increase rate detection prostate cancer compare current approach give information location tumoral volume surgery . :</brief_summary>
	<brief_title>F-18-Fluorocholine PET/CT MR Imaging/ Spectroscopy Management Primary Recurrent Prostate Cancer</brief_title>
	<detailed_description>1 . To evaluate utility F-18-FCH-PET/CT MR image 3-D MR spectroscopy detecting , localizing , estimate volume initial primary prostate cancer compare current standard work-up use TRUS-guided biopsy . All imaging finding correlate `` gold standard '' step slice histological examination . The hypothesis combination noninvasive imaging improve preoperative work-up compare current approach . 2 . To evaluate FCH-PET restaging prostate cancer biochemical relapse large patient cohort . This run parallel work-up primary prostate cancer , FCH radiopharmaceutical available time study absolutely cost patient CHUV . A number study demonstrate benefit F-18-FCH-PET/CT patient indication currently reimburse Swiss obligatory health insurance provider .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>PRIMARY PROSTATE CANCER Age ≤ 80 year Karnofsky index ≥ 80 First prostate biopsy Presence least one following : Total PSA 10 ng/mL Total PSA 2.510 ng/mL freePSA &lt; 20 % and/or PSA velocity 0.75 ng/mL/year Suspicious hypoechoic lesion TRUS and/or suspicious find digital rec¬tal examination Informed sign consent . Impaired capacity consent Coexistence clinicallyproven prostate cancer Neoadjuvant hormonal treatment ( include 5α reductase inhibitor ) Contraindications surgery Contraindications MR Imaging ( see ) PROSTATE CANCER RELAPSE Age ≤ 90 year Karnofsky index ≥ 80 Previous treatment prostate cancer No clinical recurrence base standard workup ( abdominal / pelvic CT , MRI , bone scintigraphy ) Biochemically proven relapse prostate cancer ( PSA &gt; 0.2 ng/mL prostatectomy , nadir PSA+2 ng/mL ( Phoenix definition ) ≤ 3 successive rise PSA level ( ASTRO definition ) curative radiotherapy ) . Informed signed consent . Coexistence another clinicallyproven cancer Contraindications surgery radiation therapy treatment</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Imaging</keyword>
	<keyword>Positron emission tomography</keyword>
	<keyword>F-18-FCH</keyword>
	<keyword>Magnetic resonance imaging</keyword>
	<keyword>Magnetic resonance spectroscopy</keyword>
</DOC>